Drug Abuse Screening in the Emergency Department

Home - Biochip

Drug Abuse Screening in the Emergency Department

News       About Us        Randox Toxicology

21 October 2019

 

Drug Abuse Screening in the Emergency Department

On a global scale, emergency departments have been providing critical access to the health care system for many years, however, more recently visits to the emergency department has been an opportunity to identify patients with substance use disorders. Screening patients for illicit drugs and drug abuse has become increasingly more regular when a patient is admitted to the emergency department. Screening is vital to treat a patient with effective treatment. Nearly half of all emergency department visits in the US are categorized as relating to substance use disorders.

In a study completed at Ghent University Hospital in 2017  it was found that the most frequently reported drugs abused by emergency department patients are cannabis, cocaine, amphetamines, and opiates. It is important to screen patients in the emergency department if the patient is showing signs of confusion, deliriousness, unconsciousness, panic attacks, chest pain, difficulty breathing, vomiting, or seizures as these symptoms usually indicate drug intoxication or overdose.

Randox Toxicology’s Evidence MultiSTAT is a fully automated immunoanalyser that enables on-site simultaneous detection of up to 21 analytes from a single sample, making it ideal for an emergency department. It requires a small sample volume and generates results in 20 minutes. The process from sample entry to results can be completed in 3 simple steps, with minimum room for human error. The MultiSTAT is designed to analyse as quick, simple and reliable as possible.

 

Available Tests
AB-CHMINACA AB-PINACA Amphetamine
Barbiturates Benzodiazepines I (Oxazepam) Benzodiazepines II (Lorazepam)
Benzoylecgonine (Cocaine Metabolite) Buprenorphine Cannabinoids (THC)
Creatinine Ethyl Glucuronide (EtG) Fentanyl
LSD Methadone Methamphetamine
Opiate Oxycodone Phencyclidine (PCP)
Pregabalin Propoxyphene Tramadol
Tricyclic Antidepressants (TCA) UR-144/XLR-11 α-PVP (Flakka)

 

If you would like to find out more about the Evidence MultiSTAT, Biochip Array Technology, or our Evidence range of analysers, contact info@randoxtoxicology.com or visit www.randoxtoxicology.com

 

Visit Randox Toxicology

Randox Toxicology Products and Services

BIOCHIP

EVIDENCE

ELISA

MATRICES

Want to know more about Randox?

Contact us or visit our homepage to view more.


World Heart Day from Randox Biosciences

News       About Us        Randox Biosciences

29 September 2019

 

World Heart Day 2019

 

The World Heart Federation (WHF) is the acting global voice in leading the universal fight against cardiovascular disease (CVD).  Part of the WHF mission is to ensure heart health equity for everyone. They believe everybody is entitled to cardiovascular health and well-being through health promotion, access to prevention, control and management of CVD 1.

World Heart Day falls on the 29th September where people make a promise to promote and implement healthier lifestyles to maintain a happy and healthy heart, reducing the potential risks of heart disease and stroke.  CVD takes the lead being the number one cause of death world-wide 2 relating to all heart and circulatory diseases consisting of coronary heart disease, angina, heart attack, congenital heart disease, hypertension, stroke and vascular dementia 3.

According to the World Health Organisation2:

  • An estimated 17.9 million people died from CVD in 2016, representing 31% of all global deaths. Of these deaths, 85% were due to heart attack and stroke.
  • Out of the 17 million premature deaths (under the age of 70) due to noncommunicable diseases in 2015, 82% were in low- and middle-income countries, and 37% were caused by CVD.
  • Most cardiovascular diseases can be prevented by addressing behavioural risk factors such as tobacco use, unhealthy diet and alcohol abuse.
world-heart-day-2019

Cytokines have a central role within the immune system; they are a category of signalling molecules that mediate and regulate immunity, inflammation and hematopoiesis 4.  Cytokine and inflammatory mechanisms have major implications for the vascular system and can lead to CVD.

Cytokines exist in broad families that are structurally related but exhibit diverse function.  The major classes of cytokines include: pro- and anti-inflammatory cytokines, cytokines of neutrophil and eosinophil recruitment and activation, cytokines derived from T-helper (Th) and T-regulatory (Tregs) cells, and cytokines of T-cell recruitment and growth factors.

Randox offers a comprehensive menu of 26 cytokine, cytokine receptors and growth factors over four multi-analyte arrays.  Each cytokine assay is performed on biochip array technology with spatially discrete test regions containing antibodies specific to each of the analytes.  The combination of highly specific antibodies and advanced chemistries enables up to 12 cytokines and growth factors to be detected simultaneously in a single sample.

Cytokine Array I                                                            Cytokine Array III

  • Epidermal Growth Factor (EGF) –    Granulocyte Macrophage Colony Stimulating
  • Interferon-y –    Interleukin-5
  • Interleukin-1a –    Interleukin-15
  • Interleukin-1b –    Macrophage Inflammatory Protein-1a
  • Interleukin-2
  • Interleukin-4
  • Interleukin-6
  • Interleukin-8
  • Interleukin-10
  • Monocyte Chemotactic Protein-1
  • Tumour Necrosis Factor-a
  • Vascular Endothelial Growth Factor

Cytokine Array IV                                                                         Cytokine Array V

  • Matrix Metalloproteinase-9 –    Interleukin-3
  • Soluble IL-2 Receptor a –    Interleukin-7
  • Soluble IL-6 Receptor –    Interleukin-13
  • Soluble Tumour Necrosis Factor Receptor I –   Interleukin-12 p70
  • Soluble Tumour Necrosis Factor Receptor II –   Interleukin-23

Key Benefits of Randox Cytokine Arrays:

  • Multiplex testing from a single sample.
  • Suitable for human serum and plasma samples.
  • Small sample volume required.
  • Excellent analytical performance.
  • Fast throughput.
  • Applicable to fully automated and semi-automated Evidence analysers.

Randox manufacture the majority of assay raw materials in-house and can therefore take a more tailored approach, by adapting assays to the needs of your research project to best fit your individual requirements.

  1. https://www.world-heart-federation.org/
  2. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
  3. https://www.bhf.org.uk/informationsupport/conditions/cardiovascular-disease
  4. https://www.sinobiological.com/cytokine-rerview-receptor-source-targets-main-function-disease-association-a-1310.html
  5. https://www.sciencedirect.com/topics/neuroscience/cytokines
Visit Randox Biosciences

Randox Biosciences Products and Services

RESEARCH

BIOPHARMA

CLINICAL LAB

BIOREAGENTS

Want to know more about Randox?

Contact us or visit our homepage to view more.


Metabolic Syndrome Arrays from Randox Biosciences

News       About Us        Randox Biosciences

17 September 2019

 

Metabolic Syndrome Arrays from Randox Biosciences

 

Metabolic syndrome is described as a combination of diabetes, high blood pressure and obesity. As result of three health conditions going on, it puts the individual at greater risk of developing coronary heart disease, stroke and many other risks. 1 As well as developing additional health conditions it can cause damage to the blood vessels, the blood pressure damages the blood vessels, the obesity causes a lot of strain on the blood vessels and the heart.2 Therefore, can result in serious long-term risks.

This serious health condition is very common, and studies state that it affects about 23% of adults. 3One in four adults in the UK are currently living with metabolic syndrome and often becomes more common with age2.

Usually it affects those who are overweight or considered obese, have an unbalanced diet containing high levels of sugar and fat and have high cholesterol and extremely high blood pressure2 therefore, the condition can be prevented by reducing the risks.

1 According to the NHS, metabolic syndrome occurs when a person has three or more of the following measurements:

-Abdominal obesity (Waist circumference of greater than 40 inches in men, and greater than 35 inches in women)

-Triglyceride level of 150 milligrams per deciliter of blood (mg/dL) or greater

– HDL cholesterol of less than 40 mg/dL in men or less than 50 mg/dL in women

– Systolic blood pressure (top number) of 130 millimeters of mercury (mm Hg) or greater, or diastolic blood pressure (bottom number) of 85 mm Hg or greater

There are many ways to prevent metabolic syndrome from developing, making lifestyle changes for example, ensuring their weight is healthy by increasing physical exercise, eating a well-balanced healthy diet containing whole grains, fruit, vegetables and fish and finally, visiting the GP to monitor and manage blood glucose, blood cholesterol and blood pressure, quit smoking and managing your stress.

Randox offers the Evidence Evolution including two Metabolic Syndrome Arrays which allows multiplex testing from a single sample allowing rapid turnaround time and are suitable for both serum and plasma samples.

 

 

metabolic syndrome

Metabolic Syndrome Array I

  • Ferritin
  • Interleukin-6 (IL-6)
  • Insulin
  • Leptin
  • Plasminogen Activator Inhibitor-1 (PAI-1)
  • Resistin

Metabolic Syndrome Array II

  • Adiponectin
  • C-reactive Protein (CRP)
  • Cystatin C

Want to know more about Randox?

Contact us or visit our homepage to view more.


Multiplex biochip for accurate differentiation of stroke types launched at AACC

Stroke        Biochip        MultiSTAT

05 August 2019

Stroke Biochip

 

A ground-breaking new test which improves the accuracy of stroke diagnosis has been developed by Randox scientists.

The Randox Stroke Biochip is a rapid and highly sensitive blood test that will complement and enhance existing CT scanning technology to facilitate accurate classification of stroke patients and improve patient care pathways.

With a unique ability to differentiate between ischaemic and haemorrhagic stroke, the Randox Stroke Biochip takes less than 30 minutes to complete – making sure patients get the right diagnosis as fast as possible.

Dr Peter FitzGerald, Managing Director of Randox Laboratories, whose team developed the test, commented;

“There is great tragedy in the fact that the majority of stroke damage can be minimised if intervention is delivered on time, yet too often the window closes before a diagnosis is made. For doctors, nothing is more frustrating.

“Excellent work has been undertaken to assist the public in recognising the signs of a stroke so people can get to hospital as quickly as possible. Our stroke test is the vital next step – assisting clinicians in making a rapid diagnosis and differentiation between haemorrhagic and ischaemic stroke, so their patients get the right treatment at the right time.”

Using Randox revolutionary patented Biochips, the Randox Stroke Biochip provides a unique solution for simultaneous detection of multiple stroke biomarkers from a single sample, facilitating fast and accurate classification of stroke patients in an emergency setting.

 

Benefits of the Randox Stroke Biochip

  • Results in 30 minutes on the Evidence MultiSTAT
  • Unique solution for stroke classification
  • Differentiation of ischaemic and haemorrhagic stroke
  • Guarantees rapid thrombolytic therapy ensuring better patient outcomes

 

John Lamont, R&D Director for Randox Laboratories, explained the benefits of the Stroke Biochip;

 “While patients undergo a CT scan to confirm either the presence or lack of a haemorrhagic stroke, a blood test on the Randox Biochip can be run on our innovative point-of-care analyser, the Evidence MultiSTAT, to identify the same for an ischaemic stroke.

“For the almost 90% of stroke patients who are ruled out for haemorrhagic stroke1, the Randox Biochip will then accelerate decision making for clinicians with regards to thrombolytic therapy.

 “Any treatment is most effective if started as soon as possible after the stroke occurs, and so every minute that passes without a diagnosis is likely to leave a permanent mark on a stroke patient’s future health and lifestyle.  The vitally important diagnostic information from the Randox Stroke Biochip facilitates accurate stroke classification, directs the appropriate patient care pathway, and enables rapid thrombolytic therapy, ensuring a better patient outcome for ischaemic stroke sufferers, for whom time is of the essence.”

Whilst the Randox Stroke Biochip is currently being used as complementary testing in parallel with CT scanning, Mr Lamont is confident of a more prominent role for the test in the future patient pathway;

“The Biochip has the potential to really revolutionise the stroke diagnosis pathway as we currently know it. The accessibility of this type of blood testing could potentially extend its use beyond the A&E department, to ambulances and even the home, in the form of a hand-held testing device.”

For further information about our pioneering Stroke Biochip please visit us at stand 1101 at this year’s AACC or follow the links below.

 

Want to know more?

Contact us or visit our Stroke Biochip page to learn more.

Related Products

MULTISTAT

EVIDENCE SERIES

BIOCHIP

CEREBRAL ARRAY


New test for accurate differentiation of stroke types launched at Goodwood FOS Future Lab

A ground-breaking new test which improves the accuracy of stroke diagnosis has been developed by Randox scientists.

The rapid and highly sensitive blood test, which is due to be unveiled at this year’s Goodwood Festival of Speed, can uniquely differentiate between ischaemic strokes (a blood clot) and haemorrhagic strokes (a bleed) and subsequently enable clinicians to rapidly administer the most effective treatment, which is a vital factor in limiting permanent damage.

What’s even more remarkable is that the pioneering diagnostic, appearing as part of the festival’s Future Lab exhibition, takes less than 30 minutes to complete – making sure patients get the right diagnosis as fast as possible.

Dr Peter FitzGerald, Managing Director of Randox Laboratories, whose team developed the test, commented;

“There is great tragedy in the fact that the majority of stroke damage can be minimised if intervention is delivered on time, yet too often the window closes before a diagnosis is made. For doctors, nothing is more frustrating.

“Excellent work has been undertaken to assist the public in recognising the signs of a stroke so people can get to hospital as quickly as possible. Our stroke test is the vital next step – assisting clinicians in making a rapid diagnosis and differentiation between haemorrhagic and ischaemic stroke, so their patients get the right treatment at the right time.”

Traditionally the first step in a stroke diagnosis is a CT scan, which, despite its ability to successfully diagnose haemorrhagic stroke, is significantly less capable of identifying ischaemic stroke.

Yet ischaemic stroke is the most common type of stroke and affects almost nine in ten patients.  Its diagnosis and differentiation from haemorrhagic stroke is vital in enabling thrombolytic treatment to break down blood clots, which, given its nature, could be fatal if administered to a patient suffering from a haemorrhagic stroke. Worryingly though, in some areas of the UK, as little as 15% of eligible stroke patients receive this therapy in time.1

This is caused by a number of factors, including difficulty in determining stroke onset time, exceeding the appropriate time window for thrombolysis administration (4.5 hours from stroke onset), and importantly, not being able to differentiate ischaemic stroke from a number of other ‘stroke mimics’ including severe migraine, brain tumours, drug overdose and seizures.

The Randox Stroke Biochip successfully identifies ischaemic stroke in a rapid test which measures eight markers from a single blood sample simultaneously, in just 30 minutes.

John Lamont, R&D Director for Randox Laboratories, explained;

 “While patients undergo a CT scan to confirm either the presence or lack of a haemorrhagic stroke, a blood test on the Randox Biochip can be run on our innovative point-of-care analyser, the MultiSTAT, to identify the same for an ischaemic stroke.

“For the almost 90% of stroke patients who are ruled out for haemorrhagic stroke2, the Randox Biochip will then accelerate decision making for clinicians with regards to thrombolytic therapy.

 “Any treatment is most effective if started as soon as possible after the stroke occurs, and so every minute that passes without a diagnosis is likely to leave a permanent mark on a stroke patient’s future health and lifestyle.  The vitally important diagnostic information from the Randox Stroke Biochip facilitates accurate stroke classification, directs the appropriate patient care pathway, and enables rapid thrombolytic therapy, ensuring a better patient outcome for ischaemic stroke sufferers, for whom time is of the essence.”

Whilst the Randox Stroke Biochip is currently being used as complementary testing in parallel with CT scanning, Mr Lamont is confident of a more prominent role for the test in the future patient pathway;

He commented;

“The Biochip has the potential to really revolutionise the stroke diagnosis pathway as we currently know it. The accessibility of this type of blood testing could potentially extend its use beyond the A&E department, to ambulances and even the home, in the form of a hand-held testing device.”

For further information about our pioneering new stroke test, or about the Goodwood Festival of Speed Future Lab, please contact Amy McIlwaine in the Randox PR team by emailing amy.mcilwaine@randox.com 

References

1 Royal College of Physicians Sentinel Stroke National Audit Programme (SSNAP). Clinical audit Jan – Mar 2016 report prepared by Royal College of Physicians, Clinical Effectiveness and Evaluation Unit on behalf of the Intercollegiate Stroke Working Party.

2 Intercollegiate Stroke Working Party. National clinical guideline for stroke, 5th edition. London: Royal College of Physicians 2016.

 

 

 

 

 

 

 

 

 

 


Alzheimer’s Disease testing on the Randox Evidence Series

What is Alzheimer’s Disease?

Alzheimer’s Disease is a progressive disease and is one of the most common kinds of dementia.

Our brains are made up of billions of tiny nerve cells which connect to each other. However, if you have Alzheimer’s Disease the connections between the cells are lost, which results in the loss of brain tissue and causes nerve cells to die1.

The brain is responsible for sending signals between cells. Those who suffer with Alzheimer’s have less ‘chemical messengers’ in their brain, so the signals are not passed on as well1.

The statistics of those who suffer with dementia is increasingly high and the figure is set to rise in the foreseeable future. Over 850,000 people are living with dementia in the UK. Studies states that one million people in the UK will have dementia in 2025 and this will increase to two million by 2050.2

Symptoms of Alzheimer’s Disease

The symptoms of Alzheimer’s disease are divided into 3 main stages; early symptoms, middle-stage symptoms and later symptoms.

In the early stages, the main symptom of Alzheimer’s disease is memory lapses which can increase anxiety or agitation. In the early stages, it is often mistaken that the person is forgetful and aren’t aware they are suffering with Alzheimer’s. The typical signs are listed below:3

  • forget about recent conversations or events
  • misplace items
  • forget the names of places and objects
  • have trouble thinking of the right word
  • ask questions repetitively
  • show poor judgement
  • become less flexible and more hesitant to try new things

As the disease progresses, the symptoms will gradually get worse. Memory problems will get worse which can make it difficult for the person who suffers with the disease to remember names of their loved ones, recent events and even remember birthdays and anniversaries. More symptoms such as the following will develop;3

  • increasing confusion and disorientation – for example, getting lost, or wandering and not knowing what time of day it is
  • obsessive, repetitive or impulsive behaviour
  • delusions or feeling paranoid and suspicious about carers or family members
  • problems with speech or language
  • disturbed sleep
  • changes in mood
  • difficulty performing simple tasks and may need additional support e.g. help with eating, getting dressed etc.

In the later stages of Alzheimer’s disease, the symptoms become increasingly severe and patients will need full-time care and assistance. It will be problematic for the individual to do basic everyday tasks such as getting changed, going to the toilet, getting washed and feeding themselves. They could lose their speech, and have difficulty eating and swallowing which can result in severe weight loss.

How Randox can help

Randox want to help. Our Evidence immunoanalyser has revolutionised laboratory screening worldwide with the capability to process 3,960 tests per hour and a sample capacity of 360. We offer the Apolipoprotein E4 (ApoE4) Array for Alzheimer’s genetic risk assessment, which is a research use-only product developed for the Evidence Investigator. The ApoE4 Array measures both total ApoE protein levels and ApoE4 protein levels directly from plasma samples and using a ratio can classify patients as negative or positive for ApoE4. In turn we can then assess their risk for the development of Alzheimer’s disease.

For further information about the Randox Alzheimer’s Array or our Evidence Investigator, please email info@randoxbiosciences.com       

 

  1. https://www.alzheimers.org.uk/about-dementia/types-dementia/alzheimers-disease
  2. https://www.dementiastatistics.org/statistics-about-dementia/prevalence/
  3. https://www.nhs.uk/conditions/alzheimers-disease/symptoms/

 

 

 

 

 

 

 

 

 


Raising awareness of sexual health on National STIQ Day

National STIQ Day

National STIQ day was introduced in 2010 and every year since then the 14th of January has been dedicated to raising awareness for STIQ.  The purpose is to emphasize the importance of sexual health and to encourage everyone to get regular health checks.

Sexually Transmissible Infections (STIs) are infections passed from one person to another through unprotected vaginal, oral, or anal sex, or genital contact.

Lack of symptoms

More and more people in the UK are catching STIs and each year the infection rate is rising. According to The World Health Organization (WHO), more than 1 million STIs are acquired every day and the majority of these STIs have no symptoms.1 Therefore you could have an STI and not be aware. 70% of women and 50% of men show no symptoms after contracting Chlamydia which is the most common STI condition in the UK.

Even though the majority of the time symptoms of STIs aren’t visible, there can be signs of having an STI, including unusual discharge from the vagina, penis or anus, pain when peeing, lumps or skin growth around the genitals, a rash, unusual bleeding, itchiness or blisters around the genitals.3

What to do when you catch an STI

Anyone can catch an STI regardless of what age you are, your sexuality or how many sexual partners you have, as it only takes one sexual encounter to put you at the risk of catching an STI. A shocking fact from Public Health England shows that a case of chlamydia or gonorrhea is diagnosed in a young person every 4 minutes in England, and over 144,000 diagnoses of these sexually transmitted infections are seen in people aged 15 to 24 in 2017. 4

It is extremely important to get routinely tested. The earlier the diagnosis is made and treated the less chance of having long-term effects including infertility.

Randox Biosciences 10-plex STI test

Randox Biosciences would like to take the opportunity to support STIQ day by offering our CE marked 10-plex STI test, a cost-effective solution for accurate STI testing. This test detects the following 10 infections simultaneously from a single patient urine sample.

  • Neisseria gonorrhoea (NG)
  • Mycoplasma genitalium (MG)
  • Ureaplasma urealyticum (UU)
  • Chlamydia trachomatis (CT)
  • Trichomonas vaginalis (TV)
  • Haemophilus ducreyi (HD)
  • Mycoplasma hominis (MH)
  • Treponema pallidum (TP)
  • Herpes simplex virus 1 (HSV-1)
  • Herpes simplex virus 2 (HSV-2)

Does your laboratory or clinic carry out STI testing? Our molecular analyser, the Bosch Vivalytic, powered by our award winning Biochip Array Technology, could be the diagnostic solution.

For more information about our STI Arrays or Vivalytic email: info@randoxbiosciences.com

  1. https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis)
  2. http://www.national-awareness-days.com/stiq-day/
  3. https://www.gov.uk/government/news/an-sti-is-diagnosed-in-a-young-person-every-4-minutes-in-england
  4. https://www.nhs.uk/conditions/sexually-transmitted-infections-stis/

 

 

 


RCLS and Multiplex Sexually Transmitted Infections

The Randox Clinical Laboratories Services (RCLS) team strives to meet the time sensitive, custom-made requirements of research and clinical projects. Accordingly, RCLS is also able to provide support and guidance. They specialise in biomarker and multiplex testing which provide full laboratory services to aid project aims and timelines whilst saving time and money. Currently, there are four laboratories across the UK located in Liverpool, London, Holywood and the Randox Science Park in Antrim.

In 2017 approximately 422,000 diagnoses of STIs were made in England1 and over one million STIs are acquired every day 2.

Sexually transmitted infections (STIs) are a viral or bacterial infection passed from one person to another through unprotected sexual contact.3 Most STIs are curable however, it takes time for the symptoms to appear or show up in tests. Others have no cure, such as HIV, but can be treated to prevent the disease getting worse. Common symptoms of STIs include vaginal discharge, urethral discharge or burning in men, genital ulcers, and abdominal pain 2 although, a person can have an STI without having obvious symptoms of disease.

Randox Clinical Laboratory Services offers a multiplex sexually transmitted infection array allowing you to outsource sample STI testing. It includes common STIs such as Chlamydia, Gonorrhoea, Syphilis, Herpes Simplex I, Herpes Simplex II. The full Multiplex Array can be seen below.

The simultaneous detection is made possible by our award-winning and innovative Biochip Array Technology which utilises multiplex testing methodology in a rapid and accurate format. The type of sample which is sent to our RCLS lab is determined by the visibility of the symptoms. Non-visible symptoms will require a urine sample whereas visible symptoms will require a swab sample.

There are many benefits to outsourcing your STI samples with RCLS, which include the following:

  • CE-marked
  • ISO17025 Accredited Laboratories
  • Excellent precision, specificity, sensitivity and accuracy for diagnosis
  • Reduced risk of false reporting and a reduced number of unnecessary tests
  • Smaller sample volumes are required therefore enabling faster throughput and rapid patient diagnosis

STI Multiplex Array:

  • Chlamydia trachomatis
  • Neisseria gonorrhoea
  • Herpes simplex 1
  • Herpes simplex 2
  • Treponema pallidum
  • Mycoplasma hominis
  • Ureaplasma urealticum
  • Mycoplasma genitalium
  • Haemophilius ducreyi
  • Trichomonas vaginalis

If you would like more information on RCLS or our STI testing please contact info@rcls.com

  1. https://www.gov.uk/government/news/new-data-reveals-420000-cases-of-stis-diagnosed-in-2017
  2. http://www.who.int/en/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis)
  3. https://sexualhealthdorset.org/sexually-transmitted-infections-stis

 

 

To find out more about our Biochip Array Technology and our Evidence Series analysers, visit www.randoxtoxicology.com, or email us at info@randoxtoxicology.com


Researching the Evidence Investigator

The Evidence Investigator analyser is based on the award-winning Biochip Array Technology (BAT). Biochip Array Technology is a multi-analyte testing platform allowing the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample.

The Evidence Investigator is a semi-automated benchtop analyser which is tailored for the areas of research, forensic, clinical, molecular and veterinary testing. The key feature is the fast turn-around time the Evidence Investigator can process up to 44 results from a single sample, with a maximum throughput of up to 2375 tests per hour. The Evidence Investigator saves time because it will carry out multiplex testing which will allow multiple tests to be carried out from a single patient sample which in return will save time and resources. The machine is more suitable for medium throughput laboratories.

The technology offers a wide-ranging and diverse test menu which will benefit the research areas immunology, metabolic, Sport & Exercise, oncology and cardiovascular.  Randox Research provides the Evidence Investigator to the five research areas to help their research become more efficient, cost effective and accurate.

Randox works extremely hard with their research and development, over 16% of turnover is reinvested in R&D. The current collaboration Randox works along with are Royal Victoria Hospital, Queen’s University Belfast and Cambridge University.

Randox Biosciences are dedicated to assisting research projects to completion and will make available the technology to ensure the universities receive highly accurate results for their research. Randox creates their products in-house therefore provides the flexibility of the research project. Randox can provide the university a full range of arrays, biomarkers and analysers to meet their requirements of the research.

Within Cardiovascular Research, Randox offer a comprehensive menu of cytokines. The combination of highly specific antibodies and advanced chemistries enables cytokines, cytokine receptors and growth factors to be detected simultaneously in a single sample, providing valuable information relating to each cytokine under test and possible associations between cytokines in each sample which will benefit the research. Randox offer excellent tools for universities and hospitals researchers such as routine and novel assays and can provide research analysers such as the Evidence Investigator which is suitable for medium sized laboratory.

Oncology Research has 20 biomarkers that can be custom-made to be used on the Biochip. Randox Biosciences offers a wide and extensive test menu to researchers to enable the specific product tailored to meet their clinical trail requirements.

Metabolic & Nutrition Research is another area Randox offers a wide-ranging range of tests specifically directed to Metabolic and Nutrition Research. Randox offers reagents and arrays on the award-winning Biochip Array Technology.

For more information on our Research areas and the tests that we can provide, contact us at – Info@RandoxBiosciences.com


The key features and benefits of Biochip Array Technology

Biochip Array Technology

In 1992, Randox invested £180 million to create and introduce Biochip Array Technology (BAT) which converted laboratory testing. Randox came up with the innovation by recognising the major problem with traditional diagnosis. Within traditional diagnosis several tests are typically required which involves multiple blood draws from the patient, many visits to the hospital, increased reagent volume and increased time to diagnosis. Biochip Array Technology allows for the simultaneous quantitative or qualitative detection of a wide range of analytes from one single sample. Therefore, it is faster, cost saving and more effective leading to better clinical decisions. Today the technology (BAT) is used in countless laboratories worldwide and a range of three biochip analysers are now offered.

The main basis of the Biochip Array Technology

  • 9x9mm biochip which acts as a solid phase reaction vessel.
  • Each of the biochips are pre-coated with an array of discrete test regions (DTRs)
  • One biochip per sample used to generate multiple results.
  • Randox Biochips hold up to 49 tests.
  • Based on chemiluminescent signal emitting light, without heat which results a chemical reaction.

The key features and benefits of the Biochip Array Technology

Highly accurate testing
  • The biochip array technology provides high standard of accurate test results with CV’s <10%
  • Multiplex analysis minimises analytical variation between the tests.
Better diagnosis
  • Increased patient information available through testing multiple markers
  • Patients receive their results quicker compared to the traditional diagnosis.
 Reduced sample volume
  • Reduced sample required therefore patients feel more at ease.
Wide test menu
  • Wide test menu provides a variety for clients and allows flexibility.
Multiple samples
  • Multiple samples can be used on BAT which include the following; serum, plasma, whole blood, urine and many others which allows for flexibility in their testing
Cost consolidation

–  The process reduces the amount of time spent on individual tests and associated laboratory costs

Biochip testing platforms

Evidence Evolution

The Evidence Evolution is fully automated random-access biochip testing platform. The machine allows any test to perform at any time as it is a highly versatile analyser which can operate any workflow. It can receive 2640 tests per hour which means the machine has a fast turnaround time. As well as this, it allows multiple tests to be performed from a single sample which reduces time and resources spent on individual tests. The Evidence Evolution can be tailored to certain laboratory needs and have features including automatic start-up and shut down, relaxed testing capability and traceability of biochips. The equipment overall is made to be easy for the client to use as it includes customisable user settings and easy to follow result screens giving them the fast and accurate operations they would prefer.

Evidence

The Evidence Analyser is the protein Biochip Array technology. Like the Evidence Evolution it is fully automated which is suitable for busy laboratories, hospitals, forensic and clinical toxicology. The machine is floor standing and can receive up to 3690 per hour. The machine has features such as easy to follow software and customisable user settings which gives laboratories the opportunity to receive fast and accurate results.

Evidence investigator

The Evidence Investigator is often used for research, clinical, forensic, molecular and veterinary testing.  The machine is semi-automated and can combine immunoassay and molecular diagnostics on a single platform with protein and DNA biochips. This machine also has a quick turnaround time with the ability to achieve 2376 tests per hour with 44 analytes screened per biochip. The evidence investigator provides more tests on the test menu which allows variety.

Evidence MultiSTAT

The final platform is the Evidence MultiSTAT. The Evidence MultiSTAT is a fully-automated analyser which provides quality results. It is a simple and easy to use analyser which requires minimal training with only three steps to complete the process. The machine can provide multiplex testing yields up to 46 results in under ten minutes. It is ease-of-use for non-laboratory staff and provides full traceability of user action with password controlled software.

For more information on our Biochip Array Technology contact the Randox Biosciences team by emailing info@Randoxbiosciences.com

 

 

 

 


Request a meeting
×
Make an Enquiry - RX series
×
Make an Enquiry - Reagents
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
×
Make an Enquiry - Quality Control
×
Make an Enquiry - RIQAS
×
Make an Enquiry - RIQAS
×
Make an Enquiry - Quality Control
×
Make an Enquiry
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Biochip
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Molecular
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Future Diagnostics
×
Make an Enquiry - RX series (Product)
×
Make an Enquiry - Quality Control
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - RIQAS
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Por favor, introduzca sus datos para ver nuestro último seminario
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje Polityki Prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
    Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności .
×
귀하의 문의 사항 제출
    Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
귀하의 문의 사항 제출
×
귀하의 문의 사항 제출
×
귀하의 문의 사항 제출
×
Downloads
×
Contact

<p>

    Randox Clinical Chemistry Products Join the Randox Laboratories Mailing List * I would like to receive emails with new product releases and updates from Randox Laboratories, market trends, and more. I do not want to receive email marketing from Randox. Signing up to our mailing list is quick and easy. We do not want to send you any spam or junk emails, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promises never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
</p>

×
Clinical Laboratory Survey